Slingshot members are tracking this event:

Phase 2 additional data of VK2809 in Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease to be presented at EASL April 11, 2019, 09:00 AM CEST

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
VKTX Community voting in process
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Vk2809, Hypercholesterolemia, Nafld, Easl 2019